From Evidence to Execution: Pharmacists Navigate MRA Selection and Access in HFpEF and HFmrEF

As treatment options expand for heart failure with preserved ejection fraction (HFpEF) and mildly reduced ejection fraction (HFmrEF), pharmacists are increasingly responsible for translating clinical evidence into individualized, sustainable care. In a recent Pharmacy Times Clinical Forum in Atlanta, Georgia, moderator Dejan Landup, PharmD, HF-Cert, a heart failure and cardiometabolic clinical pharmacist with Advocate Medical Group, led a panel of health system pharmacists in discussing mineralocorticoid receptor antagonist (MRA) selection, laboratory monitoring, medication access, and continuity between inpatient and outpatient settings. Although the approval of finerenone (Kerendia; Bayer) has added another treatment option for patients with left ventricular ejection fraction (LVEF) of 40% or greater, the discussion demonstrated that selecting a therapy is only one step toward improving outcomes.